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Coronavirus Disease 2019 (COVID-19)
Information for Clinicians on Therapeutic Options for
COVID-19 Patients
There are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with
COVID-19.  At present clinical management includes infection prevention and control measures and supportive care,
including supplementary oxygen and mechanical ventilatory support when indicated.  An array of drugs approved for
other indications as well as several investigational drugs are being studied in several hundred clinical trials that are
underway across the globe. The purpose of this document is to provide information on two of the approved drugs
(chloroquine and hydroxychloroquine) and one of the investigational agents (remdesivir) currently in use in the United
States.
Remdesivir
Remdesivir is an investigational intravenous drug with broad antiviral activity that inhibits viral replication through
premature termination of RNA transcription and has in-vitro activity against SARS-CoV-2 and in-vitro and in-vivo activity
against related betacoronaviruses .
There are currently four options for obtaining remdesivir for treatment of hospitalized patients with COVID-19 and
pneumonia in the United States:
A National Institutes of Health (NIH)-sponsored adaptive double-blinded, placebo-controlled trial of remdesivir
versus placebo in COVID-19 patients with pneumonia and hypoxia is enrolling non-pregnant persons aged 18 years
and older with oxygen saturation of ≤94% on room air or requiring supplemental oxygen or mechanical ventilation
(https://clinicaltrials.gov/ct2/show/NCT04280705 ). Exclusion criteria include alanine aminotransaminase or
aspartate aminotransaminase levels >5 times the upper limit of normal, stage 4 severe chronic kidney disease or a
requirement for dialysis (i.e., estimated glomerular filtration rate (eGFR) <30);
Two phase 3 randomized open-label trials of remdesivir (5-days versus 10-days versus standard of care) are open to
enrollment in persons aged 18 years and older with COVID-19, radiographic evidence of pneumonia and oxygen
saturation of ≤94% on room air (severe disease https://clinicaltrials.gov/ct2/show/NCT04292899 ) or >94% on
room air (moderate disease https://clinicaltrials.gov/ct2/show/NCT04292730 ). Exclusion criteria include alanine
aminotransaminase or aspartate aminotransaminase levels >5 times the upper limit of normal, participation in
another clinical trial of an experimental treatment for COVID-19, requirement for mechanical ventilation, or
creatinine clearance <50 mL/min; and
Finally, in areas without clinical trials, COVID-19 patients in the United States and other countries have been treated
with remdesivir on an uncontrolled compassionate use basis. The manufacturer is currently transitioning the
provision of emergency access to remdesivir from individual compassionate use requests to an expanded access
program.  The expanded access program for the United States is under rapid development. Further information is
available at: https://rdvcu.gilead.com/
Hydroxychloroquine and Chloroquine
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Hydroxychloroquine and chloroquine are oral prescription drugs that have been used for treatment of malaria and
certain inflammatory conditions. Chloroquine has been used for malaria treatment and chemoprophylaxis, and
hydroxychloroquine is used for treatment of rheumatoid arthritis, systemic lupus erythematosus and porphyria cutanea
tarda. Both drugs have in-vitro activity against SARS-CoV, SARS-CoV-2, and other coronaviruses, with hydroxychloroquine
having relatively higher potency against SARS-CoV-2 . A study in China reported that chloroquine treatment of COVID-
19 patients had clinical and virologic benefit versus a comparison group, and chloroquine was added as a recommended
antiviral for treatment of COVID-19 in China . Based upon limited in-vitro and anecdotal data, chloroquine or
hydroxychloroquine are currently recommended for treatment of hospitalized COVID-19 patients in several countries.
Both chloroquine and hydroxychloroquine have known safety profiles with the main concerns being cardiotoxicity
(prolonged QT syndrome) with prolonged use in patients with hepatic or renal dysfunction and immunosuppression but
have been reportedly well-tolerated in COVID-19 patients.
Due to higher in-vitro activity against SARS-CoV-2 and its wider availability in the United States compared with
chloroquine, hydroxychloroquine has been administered to hospitalized COVID-19 patients on an uncontrolled basis in
multiple countries, including in the United States. One small study reported that hydroxychloroquine alone or in
combination with azithromycin reduced detection of SARS-CoV-2 RNA in upper respiratory tract specimens compared
with a non-randomized control group but did not assess clinical benefit . Hydroxychloroquine and azithromycin are
associated with QT prolongation and caution is advised when considering these drugs in patients with chronic medical
conditions (e.g. renal failure, hepatic disease) or who are receiving medications that might interact to cause arrythmias.
Hydroxychloroquine is currently under investigation in clinical trials for pre-exposure or post-exposure prophylaxis of
SARS-CoV-2 infection, and treatment of patients with mild, moderate, and severe COVID-19. In the United States, several
clinical trials of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection are planned or will be enrolling
soon.  More information on trials can be found at:  https://clinicaltrials.gov/ .
There are no currently available data from Randomized Clinical Trials (RCTs) to inform clinical guidance on the use,
dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection.  Although optimal
dosing and duration of hydroxychloroquine for treatment of COVID-19 are unknown, some U.S. clinicians have reported
anecdotally different hydroxychloroquine dosing such as: 400mg BID on day one, then daily for 5 days; 400 mg BID on
day one, then 200mg BID for 4 days; 600 mg BID on day one, then 400mg daily on days 2-5.
Other Drugs
Lopinavir-ritonavir did not show promise for treatment of hospitalized COVID-19 patients with pneumonia in a recent
clinical trial in China .  This trial was underpowered, and lopinavir-ritonavir is under investigation in a World Health
Organization study.
Several other drugs are under investigation in clinical trials or are being considered for clinical trials of prophylaxis or
treatment of COVID-19 in the United States and worldwide. Information on registered clinical trials for COVID-19 in the
United States is available at: https://clinicaltrials.gov/ .
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